KR20230154227A - 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법 - Google Patents

치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법 Download PDF

Info

Publication number
KR20230154227A
KR20230154227A KR1020237033580A KR20237033580A KR20230154227A KR 20230154227 A KR20230154227 A KR 20230154227A KR 1020237033580 A KR1020237033580 A KR 1020237033580A KR 20237033580 A KR20237033580 A KR 20237033580A KR 20230154227 A KR20230154227 A KR 20230154227A
Authority
KR
South Korea
Prior art keywords
compound
cancer
therapeutically effective
effective dose
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237033580A
Other languages
English (en)
Korean (ko)
Inventor
안토니 티. 그리웨이
울리크 필리파르
토마스 시 와일드
마리 이 윌르민
Original Assignee
얀센 파마슈티카 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔브이 filed Critical 얀센 파마슈티카 엔브이
Publication of KR20230154227A publication Critical patent/KR20230154227A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237033580A 2021-03-03 2021-03-03 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법 Pending KR20230154227A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/051776 WO2022185097A1 (en) 2021-03-03 2021-03-03 Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide)

Publications (1)

Publication Number Publication Date
KR20230154227A true KR20230154227A (ko) 2023-11-07

Family

ID=74860360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033580A Pending KR20230154227A (ko) 2021-03-03 2021-03-03 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법

Country Status (10)

Country Link
US (1) US20240299376A1 (https=)
EP (1) EP4301364A1 (https=)
JP (1) JP2024508890A (https=)
KR (1) KR20230154227A (https=)
CN (1) CN117279639A (https=)
AU (1) AU2021431485A1 (https=)
BR (1) BR112023017689A2 (https=)
CA (1) CA3212339A1 (https=)
MX (1) MX2023010322A (https=)
WO (1) WO2022185097A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
CN118451068A (zh) * 2021-12-30 2024-08-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US12269813B2 (en) 2019-02-22 2025-04-08 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate
US20220175760A1 (en) * 2019-02-22 2022-06-09 Janssen Pharmaceutica Nv Pharmaceutical formulations

Also Published As

Publication number Publication date
EP4301364A1 (en) 2024-01-10
WO2022185097A1 (en) 2022-09-09
CN117279639A (zh) 2023-12-22
JP2024508890A (ja) 2024-02-28
AU2021431485A1 (en) 2023-10-19
MX2023010322A (es) 2023-11-24
BR112023017689A2 (pt) 2023-11-14
US20240299376A1 (en) 2024-09-12
CA3212339A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
JP6389241B2 (ja) 癌を治療するためのＴＯＲキナーゼ阻害剤及びＩＭｉＤ化合物を含む組合せ療法
JP7667568B2 (ja) 複素環キナーゼ阻害剤及びその使用
TW202400153A (zh) Ｋｒａｓｇ１２ｃ抑制劑之治療用途
US9364476B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
JP6382949B2 (ja) 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
US20180280408A1 (en) Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
JP2024526145A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤を含む組合せ医薬及び癌の治療のためのその使用
KR20230154227A (ko) 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법
TW201534305A (zh) 使用組合療法治療癌症之方法
CN114246864B (zh) Csf1r激酶抑制剂及其用途
TW201526894A (zh) 藉二氫吡并吡治療癌症
WO2014081712A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
KR20230154232A (ko) Malt1 억제제 및 btk 억제제를 사용하는 병용 치료
WO2014081714A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
EP2922826A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
JP2023517671A (ja) ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置
US20220226300A1 (en) A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor
US20210382037A1 (en) Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agents
Evrard et al. Apilimod in Oncology: From Non-Malignant Origins to Emerging Anti-Cancer Potential
AU2012321091B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
HK40013254A (en) An inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease
NZ629860B (en) Methods for treating cancer using tor kinase inhibitor combination therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902